Torrent Pharma (TORNTPHARM) Q4 Results Preview, Market News: Ahmedabad-based Torrent Pharma is scheduled to report its financial results for the quarter and year ended March 31, 2024, on Friday, May 24. Analysts expect the pharmaceutical company to deliver strong financial performance for the fourth and final quarter. of fiscal year 24.
According to Zee Business research, Torrent Pharma (TORNTPHARM) is estimated to register a consolidated net profit of Rs 447 crore for the January-March period, translating to an increase of 56 per cent compared to the corresponding quarter of the last year. Analysts expect the drugmaker to post 12 per cent year-on-year growth in revenue to Rs 2,796 crore for the March quarter.
Torrent Pharma is expected to post Rs 893 crore in fourth-quarter earnings before interest, taxes, depreciation and amortization (EBITDA), up 23 per cent from the year-ago period, according to Zee Business research. Analysts put the pharmaceutical company's margin, a key measure of profitability for companies, at 32 per cent for the March quarter, an improvement of 300 basis points (bps) from the same period a year earlier.
Zee Business analysts expect the pharmaceutical company to post revenue growth of around 12-13 per cent in its domestic business, and 12 per cent and 6.0 per cent in its operations in Germany and Brazil, respectively. However, they anticipate an 11 percent decline at the drugmaker's U.S. unit.
Analysts will closely monitor the Ahmedabad-based pharmaceutical company's comments on its upcoming launches.
Torrent Pharma Q3 FY24 Results: A Summary
For the quarter ended December 31, Torrent Pharma posted a consolidated net profit of Rs 443 crore and revenue of Rs 2,732 crore, up 51.7 percent and 9.7 percent compared to the same period of the previous year, respectively.
Its margin improved 300 basis points to 32 percent, according to a regulatory filing.
Torrent Pharma (TORNTPHARM) Stock: Historical Performance
Through May 23, Torrent Pharma shares have rewarded investors with a return of nearly 55 percent in a year, outpacing a 25.6 percent gain in the main Nifty50 index and in line with a rise of 53.9 percent in the Nifty Pharma index.
See all the news stock market updates here. For all other news related to business, politics, technology and automobiles, visit Zeebiz.com.
